+ All Categories
Home > Documents >  · 6. Ylldmm E, N- K, ipek E, AF, Ulusov FR- Hatem E. The evaluation of the clinical utility of...

 · 6. Ylldmm E, N- K, ipek E, AF, Ulusov FR- Hatem E. The evaluation of the clinical utility of...

Date post: 21-Jul-2020
Category:
Upload: others
View: 0 times
Download: 0 times
Share this document with a friend
17
Transcript
Page 1:  · 6. Ylldmm E, N- K, ipek E, AF, Ulusov FR- Hatem E. The evaluation of the clinical utility of urocortin I and adrenomedullin versus proBNP in systolic heart Anatol CardiaL 2017
Page 2:  · 6. Ylldmm E, N- K, ipek E, AF, Ulusov FR- Hatem E. The evaluation of the clinical utility of urocortin I and adrenomedullin versus proBNP in systolic heart Anatol CardiaL 2017
Page 3:  · 6. Ylldmm E, N- K, ipek E, AF, Ulusov FR- Hatem E. The evaluation of the clinical utility of urocortin I and adrenomedullin versus proBNP in systolic heart Anatol CardiaL 2017
Page 4:  · 6. Ylldmm E, N- K, ipek E, AF, Ulusov FR- Hatem E. The evaluation of the clinical utility of urocortin I and adrenomedullin versus proBNP in systolic heart Anatol CardiaL 2017
Page 5:  · 6. Ylldmm E, N- K, ipek E, AF, Ulusov FR- Hatem E. The evaluation of the clinical utility of urocortin I and adrenomedullin versus proBNP in systolic heart Anatol CardiaL 2017
Page 6:  · 6. Ylldmm E, N- K, ipek E, AF, Ulusov FR- Hatem E. The evaluation of the clinical utility of urocortin I and adrenomedullin versus proBNP in systolic heart Anatol CardiaL 2017
Page 7:  · 6. Ylldmm E, N- K, ipek E, AF, Ulusov FR- Hatem E. The evaluation of the clinical utility of urocortin I and adrenomedullin versus proBNP in systolic heart Anatol CardiaL 2017
Page 8:  · 6. Ylldmm E, N- K, ipek E, AF, Ulusov FR- Hatem E. The evaluation of the clinical utility of urocortin I and adrenomedullin versus proBNP in systolic heart Anatol CardiaL 2017
Page 9:  · 6. Ylldmm E, N- K, ipek E, AF, Ulusov FR- Hatem E. The evaluation of the clinical utility of urocortin I and adrenomedullin versus proBNP in systolic heart Anatol CardiaL 2017
Page 10:  · 6. Ylldmm E, N- K, ipek E, AF, Ulusov FR- Hatem E. The evaluation of the clinical utility of urocortin I and adrenomedullin versus proBNP in systolic heart Anatol CardiaL 2017
Page 11:  · 6. Ylldmm E, N- K, ipek E, AF, Ulusov FR- Hatem E. The evaluation of the clinical utility of urocortin I and adrenomedullin versus proBNP in systolic heart Anatol CardiaL 2017
Page 12:  · 6. Ylldmm E, N- K, ipek E, AF, Ulusov FR- Hatem E. The evaluation of the clinical utility of urocortin I and adrenomedullin versus proBNP in systolic heart Anatol CardiaL 2017
Page 13:  · 6. Ylldmm E, N- K, ipek E, AF, Ulusov FR- Hatem E. The evaluation of the clinical utility of urocortin I and adrenomedullin versus proBNP in systolic heart Anatol CardiaL 2017
Page 14:  · 6. Ylldmm E, N- K, ipek E, AF, Ulusov FR- Hatem E. The evaluation of the clinical utility of urocortin I and adrenomedullin versus proBNP in systolic heart Anatol CardiaL 2017
Page 15:  · 6. Ylldmm E, N- K, ipek E, AF, Ulusov FR- Hatem E. The evaluation of the clinical utility of urocortin I and adrenomedullin versus proBNP in systolic heart Anatol CardiaL 2017
Page 16:  · 6. Ylldmm E, N- K, ipek E, AF, Ulusov FR- Hatem E. The evaluation of the clinical utility of urocortin I and adrenomedullin versus proBNP in systolic heart Anatol CardiaL 2017
Page 17:  · 6. Ylldmm E, N- K, ipek E, AF, Ulusov FR- Hatem E. The evaluation of the clinical utility of urocortin I and adrenomedullin versus proBNP in systolic heart Anatol CardiaL 2017

Recommended